Research programme: ubiquitin specific protease inhibitors - Hybrigenics

Drug Profile

Research programme: ubiquitin specific protease inhibitors - Hybrigenics

Alternative Names: HBX 19,818; HBX 41,108; HBX 96,819; USP inhibitors - Hybrigenics; USP8 inhibitors - Hybrigenics

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hybrigenics
  • Class Small molecules
  • Mechanism of Action Ubiquitin protein ligase complex inhibitors; Ubiquitin-protein ligase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Pituitary ACTH hypersecretion
  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in France
  • 06 Jun 2017 Hybrigenics has patnet protection for USP8 inhibitors in Europe
  • 06 Jun 2017 Early research in Pituitary ACTH hypersecretion in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top